Article History
Accepted: 25 January 2021
First Online: 2 March 2021
Competing interests
: M.N. has received funds or material research support from Alnylam, Biotronik, CSL Behring, GlycoMimetics, GSK, Medtronic, Novartis and Pfizer, as well as consulting fees from Biogen, Gimv, IFM Therapeutics, Molecular Imaging, Sigilon, Takeda and Verseau Therapeutics. The other authors declare no competing interests.